Justin Stindt Consultants is a consulting firm specializing in Strategy & Market Access advisory services for the pharmaceutical, biotech and medical device industries.
Our agency is passionate about enabling patient access to innovative medicines and technologies. We are a service provider to pharma, biotech, medtech and e-health clients, helping to determine what clinical evidence payers will need to see in order to grant reimbursement at a sustainable price. Our team of experts leverages secondary research e.g. in Pricing & Reimbursement databases, primary research with payers and clinical experts and our agency’s experience from hundreds of Market Access projects.
Our agency has extensive international experience in all major EU markets, the US, Japan and selected emerging markets. Our team of experts operates from offices in Paris, Cologne and Zug and has a global reach through our network of payers, clinical experts and partners.
Would you like to know what our customers are saying about us?
Then have a look at our client testimonials and you will find attributes such as commitment to excellence, trusted partnerships, flexible and customized support, expert knowledge and our extensive network all engaged to enable Market Access for our client’s products.
Meet selected experts within our global team
Justin Stindt Consultants mobilizes project teams of 50+ consultants
Justin Stindt
Founder and Managing Director
Justin is an experienced Market Access strategist with a background at GlaxoSmithKline and in consulting. Justin supports pharma, biotech and medtech clients with Market Access strategy and execution. He has led hundreds of Pricing & Reimbursement projects, overseen development of Pricing & Reimbursement dossiers, led engagements with HTA bodies and conducted price negotiations on behalf of clients. Justin is fluent in English, French, German, and Spanish.
Javier Arribas Díaz
Director
With a focus on orphan drugs, Javier is experienced in advising pharmaceutical and medtech clients on market access and pricing strategies. Javier is both leading global projects and activities focused on the Spanish market such as the development of Spanish Pricing & Reimbursement strategies and dossiers. Javier has prior consulting experience at Accenture and Werfen. He studied at Kellogg School of Management in the US, did an MBA at IESE in Spain, and is proficient in Spanish and English.
Anne Stindt
Director
Anne is a health insurance specialist with a background in digital marketing and health and medical insurance purchasing at AXA where she held roles both on corporate level in the headquarter in Paris and on affiliate level in Germany. At Justin Stindt Consultants, she leads global research projects and develops Pricing & Reimbursement strategies. She is fluent in French, English, German and Portuguese and holds a Master’s degree from ESCP-EAP Business School.
Jesús Arribas
Chief Financial Officer
Jesús Arribas is a finance expert with extensive experience as a Chief Financial Officer and Management Consultant. He has led the creation and optimization of finance departments, developed long-term strategies, and improved accounting processes. His ability to advise on financial projections and audits has been key to the success of multiple companies.
Eva Brčić
Consultant
Eva specializes in strategic market access research for pharmaceutical and biotech firms. Her projects include pricing and reimbursement analysis, research in medical information and Pricing & Reimbursement databases, and expert interviews with payers and clinical experts. Eva is fluent in English, French, and Croatian and has a Master in Management and a Bachelor’s in Psychology from the Erasmus University Rotterdam.
Camille Maréchal
Consultant
Camille focuses on pricing and reimbursement strategies for pharmaceutical and biotech firms. Her recent projects focused e.g. on early access programs, EU-5 rebate structures and taxation systems. She also contributed to G-BA scientific advice meetings, analyzed real-world evidence interviews, and aided in lifecycle strategy development. Camille, fluent in French, Dutch, German, English and Spanish, holds a Bachelor’s degree in Business Administration from the University of St. Gallen (HSG).
Joaquim Mac Dowell Zurcher
Consultant
Joaquim has experience in strategic market access research for pharmaceutical and biotech companies. His projects consisted of the analysis of Pricing & Reimbursement databases and HTA appraisals in major EU markets and the US, along with the conduct of in-depth interviews with experts and payers to assess the perceived value of innovative assets and price sensitivity. Joaquim holds a Bachelor’s degree in Economics from PUC-RIO and a Master’s degree in Finance from ESSEC Business School. He is a Swiss and Brazilian citizen and speaks English, Portuguese, Spanish, and French.
Emma Berli
Consultant
Emma focuses on pricing and reimbursement strategies for pharmaceutical and biotech firms. Her projects consist of early access programs, EU-5 rebate structures and taxation systems, and analysis of Pricing & Reimbursement databases and HTA appraisals in major EU markets and the US. She also conducts in-depth interviews with experts and payers to assess the perceived value of innovative assets. Emma speaks French, English, Spanish, and German, and holds a Bachelor’s degree in Business Administration and a Master in Accounting and Corporate Finance from the University of St. Gallen (HSG).
Joaquim Knox
Consultant
Joaquim Knox is a consultant with a strong foundation in biochemistry with experience in drug development and business development in the pharmaceutical industry. Holding a Bachelor’s degree in Biological Sciences, with emphasis in Biochemistry, from UNIRIO, and a Masters degree in Pharma and Biotech Management from EADA Business School, Joaquim focuses on developing strategic Pricing and Reimbursement strategies for pharmaceutical and biotech companies. With a background spanning from preclinical strategy to clinical development in different therapeutic fields, such as Urology, Ophthalmology, Respiratory and Orphan Drugs, Joaquim brings valuable insights into the intricacies of drug development. Additionally, his work in Business Development and Licensing roles across the pharma and biotech industry, enhances his ability to navigate complex market landscapes. Joaquim is proficient in Portuguese, English and Spanish.
